Pfizer to make major investment in vaccine R&D and manufacturing site in New York
It’s been just over a month since Pfizer announced it was pumping $120 million into its Michigan facility to boost Paxlovid production, and now the Big Pharma is making another major investment in vaccine manufacturing, this time in its facility outside New York City.
According to a report from Bloomberg, Pfizer is looking to sink $470 million into expanding its vaccine research facilities at its location in Pearl River, NY, just 25 miles north of New York City. Pfizer will construct a new building as well as renovate existing facilities on the campus. The total expansion will be 260,000 square feet with an additional 55,000 square feet of lab space. The company is aiming for construction in the first quarter of 2026, the report said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.